APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastrointestinal Motility Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Gastrointestinal Motility Drugs Industry Research Report 2026

27 December 2025146 pages

Choose your research edition.

Industry ResearchGastrointestinal Motility Drugs Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastrointestinal Motility Drugs Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Gastrointestinal Motility Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastrointestinal Motility Drugs Market Outlook and Growth Opportunities 2026210 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastrointestinal Motility Drugs Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global Gastrointestinal Motility Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Gastrointestinal Motility Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Gastrointestinal Motility Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Gastrointestinal Motility Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Gastrointestinal Motility Drugs include Zhuhai Rundu Pharmaceutical Co., Ltd., Yabao Pharmaceutical Group Co., Ltd., Sichuan Zilinggong Pharmaceutical Co., Ltd., Shijiazhuang Siyao Co., Ltd., Shandong Xinhua Pharmaceutical Co., Ltd., Shandong Fangming Pharmaceutical Group Co., Ltd., Lunan Beite Pharmaceutical Co., Ltd., Jiangxi Huiren Pharmaceutical Co., Ltd. and Jiangsu Jibei Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Gastrointestinal Motility Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Gastrointestinal Motility Drugs Market by Company

Zhuhai Rundu Pharmaceutical Co., Ltd.

Yabao Pharmaceutical Group Co., Ltd.

Sichuan Zilinggong Pharmaceutical Co., Ltd.

Shijiazhuang Siyao Co., Ltd.

Shandong Xinhua Pharmaceutical Co., Ltd.

Shandong Fangming Pharmaceutical Group Co., Ltd.

Lunan Beite Pharmaceutical Co., Ltd.

Jiangxi Huiren Pharmaceutical Co., Ltd.

Jiangsu Jibei Pharmaceutical Co., Ltd.

Jiangsu Hausen Pharmaceutical Group Co., Ltd.

China Resources Double Crane Pharmaceutical Co., Ltd.

Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd.

Hainan Asia Pharmaceutical Co., Ltd.

Guangdong Annuo Pharmaceutical Co., Ltd.

Disa Pharmaceutical Group Co., Ltd.

Chenxin Pharmaceutical Co., Ltd.

Taj Pharmaceuticals Limited

Sumitomo Pharma Co., Ltd.

Pfizer

Midas Pharma GmbH

Janssen Pharmaceutica

Hanmi Pharm. Co., Ltd.

ANI Pharmaceuticals, Inc.

Abbott

Gastrointestinal Motility Drugs Segment by Type

Domperidone

Metoclopramide

Mosapride

Minaprocaine Bromide

Itopride

Gastrointestinal Motility Drugs Segment by Application

Clinic

Hospital

Other

Gastrointestinal Motility Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastrointestinal Motility Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastrointestinal Motility Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastrointestinal Motility Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Gastrointestinal Motility Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Gastrointestinal Motility Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Gastrointestinal Motility Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Gastrointestinal Motility Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Gastrointestinal Motility Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Gastrointestinal Motility Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Gastrointestinal Motility Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Gastrointestinal Motility Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Gastrointestinal Motility Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Gastrointestinal Motility Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Gastrointestinal Motility Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Gastrointestinal Motility Drugs, Product Type & Application Table 14. Global Gastrointestinal Motility Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Gastrointestinal Motility Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Zhuhai Rundu Pharmaceutical Co., Ltd. Company Information Table 19. Zhuhai Rundu Pharmaceutical Co., Ltd. Business Overview Table 20. Zhuhai Rundu Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Zhuhai Rundu Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 22. Zhuhai Rundu Pharmaceutical Co., Ltd. Recent Developments Table 23. Yabao Pharmaceutical Group Co., Ltd. Company Information Table 24. Yabao Pharmaceutical Group Co., Ltd. Business Overview Table 25. Yabao Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Yabao Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 27. Yabao Pharmaceutical Group Co., Ltd. Recent Developments Table 28. Sichuan Zilinggong Pharmaceutical Co., Ltd. Company Information Table 29. Sichuan Zilinggong Pharmaceutical Co., Ltd. Business Overview Table 30. Sichuan Zilinggong Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Sichuan Zilinggong Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 32. Sichuan Zilinggong Pharmaceutical Co., Ltd. Recent Developments Table 33. Shijiazhuang Siyao Co., Ltd. Company Information Table 34. Shijiazhuang Siyao Co., Ltd. Business Overview Table 35. Shijiazhuang Siyao Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Shijiazhuang Siyao Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 37. Shijiazhuang Siyao Co., Ltd. Recent Developments Table 38. Shandong Xinhua Pharmaceutical Co., Ltd. Company Information Table 39. Shandong Xinhua Pharmaceutical Co., Ltd. Business Overview Table 40. Shandong Xinhua Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Shandong Xinhua Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 42. Shandong Xinhua Pharmaceutical Co., Ltd. Recent Developments Table 43. Shandong Fangming Pharmaceutical Group Co., Ltd. Company Information Table 44. Shandong Fangming Pharmaceutical Group Co., Ltd. Business Overview Table 45. Shandong Fangming Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Shandong Fangming Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 47. Shandong Fangming Pharmaceutical Group Co., Ltd. Recent Developments Table 48. Lunan Beite Pharmaceutical Co., Ltd. Company Information Table 49. Lunan Beite Pharmaceutical Co., Ltd. Business Overview Table 50. Lunan Beite Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Lunan Beite Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 52. Lunan Beite Pharmaceutical Co., Ltd. Recent Developments Table 53. Jiangxi Huiren Pharmaceutical Co., Ltd. Company Information Table 54. Jiangxi Huiren Pharmaceutical Co., Ltd. Business Overview Table 55. Jiangxi Huiren Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Jiangxi Huiren Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 57. Jiangxi Huiren Pharmaceutical Co., Ltd. Recent Developments Table 58. Jiangsu Jibei Pharmaceutical Co., Ltd. Company Information Table 59. Jiangsu Jibei Pharmaceutical Co., Ltd. Business Overview Table 60. Jiangsu Jibei Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Jiangsu Jibei Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 62. Jiangsu Jibei Pharmaceutical Co., Ltd. Recent Developments Table 63. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Company Information Table 64. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Business Overview Table 65. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 67. Jiangsu Hausen Pharmaceutical Group Co., Ltd. Recent Developments Table 68. China Resources Double Crane Pharmaceutical Co., Ltd. Company Information Table 69. China Resources Double Crane Pharmaceutical Co., Ltd. Business Overview Table 70. China Resources Double Crane Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. China Resources Double Crane Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 72. China Resources Double Crane Pharmaceutical Co., Ltd. Recent Developments Table 73. Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Company Information Table 74. Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Business Overview Table 75. Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 77. Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Recent Developments Table 78. Hainan Asia Pharmaceutical Co., Ltd. Company Information Table 79. Hainan Asia Pharmaceutical Co., Ltd. Business Overview Table 80. Hainan Asia Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Hainan Asia Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 82. Hainan Asia Pharmaceutical Co., Ltd. Recent Developments Table 83. Guangdong Annuo Pharmaceutical Co., Ltd. Company Information Table 84. Guangdong Annuo Pharmaceutical Co., Ltd. Business Overview Table 85. Guangdong Annuo Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Guangdong Annuo Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 87. Guangdong Annuo Pharmaceutical Co., Ltd. Recent Developments Table 88. Disa Pharmaceutical Group Co., Ltd. Company Information Table 89. Disa Pharmaceutical Group Co., Ltd. Business Overview Table 90. Disa Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Disa Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 92. Disa Pharmaceutical Group Co., Ltd. Recent Developments Table 93. Chenxin Pharmaceutical Co., Ltd. Company Information Table 94. Chenxin Pharmaceutical Co., Ltd. Business Overview Table 95. Chenxin Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Chenxin Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 97. Chenxin Pharmaceutical Co., Ltd. Recent Developments Table 98. Taj Pharmaceuticals Limited Company Information Table 99. Taj Pharmaceuticals Limited Business Overview Table 100. Taj Pharmaceuticals Limited Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Taj Pharmaceuticals Limited Gastrointestinal Motility Drugs Product Portfolio Table 102. Taj Pharmaceuticals Limited Recent Developments Table 103. Sumitomo Pharma Co., Ltd. Company Information Table 104. Sumitomo Pharma Co., Ltd. Business Overview Table 105. Sumitomo Pharma Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Sumitomo Pharma Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 107. Sumitomo Pharma Co., Ltd. Recent Developments Table 108. Pfizer Company Information Table 109. Pfizer Business Overview Table 110. Pfizer Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Pfizer Gastrointestinal Motility Drugs Product Portfolio Table 112. Pfizer Recent Developments Table 113. Midas Pharma GmbH Company Information Table 114. Midas Pharma GmbH Business Overview Table 115. Midas Pharma GmbH Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Midas Pharma GmbH Gastrointestinal Motility Drugs Product Portfolio Table 117. Midas Pharma GmbH Recent Developments Table 118. Janssen Pharmaceutica Company Information Table 119. Janssen Pharmaceutica Business Overview Table 120. Janssen Pharmaceutica Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Janssen Pharmaceutica Gastrointestinal Motility Drugs Product Portfolio Table 122. Janssen Pharmaceutica Recent Developments Table 123. Hanmi Pharm. Co., Ltd. Company Information Table 124. Hanmi Pharm. Co., Ltd. Business Overview Table 125. Hanmi Pharm. Co., Ltd. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Hanmi Pharm. Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio Table 127. Hanmi Pharm. Co., Ltd. Recent Developments Table 128. ANI Pharmaceuticals, Inc. Company Information Table 129. ANI Pharmaceuticals, Inc. Business Overview Table 130. ANI Pharmaceuticals, Inc. Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. ANI Pharmaceuticals, Inc. Gastrointestinal Motility Drugs Product Portfolio Table 132. ANI Pharmaceuticals, Inc. Recent Developments Table 133. Abbott Company Information Table 134. Abbott Business Overview Table 135. Abbott Gastrointestinal Motility Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Abbott Gastrointestinal Motility Drugs Product Portfolio Table 137. Abbott Recent Developments Table 138. Global Gastrointestinal Motility Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 139. Global Gastrointestinal Motility Drugs Sales by Region (2021-2026) & (K Units) Table 140. Global Gastrointestinal Motility Drugs Sales Market Share by Region (2021-2026) Table 141. Global Gastrointestinal Motility Drugs Sales by Region (2027-2032) & (K Units) Table 142. Global Gastrointestinal Motility Drugs Sales Market Share by Region (2027-2032) Table 143. Global Gastrointestinal Motility Drugs Revenue by Region (2021-2026) & (US$ Million) Table 144. Global Gastrointestinal Motility Drugs Revenue Market Share by Region (2021-2026) Table 145. Global Gastrointestinal Motility Drugs Revenue by Region (2027-2032) & (US$ Million) Table 146. Global Gastrointestinal Motility Drugs Revenue Market Share by Region (2027-2032) Table 147. North America Gastrointestinal Motility Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. North America Gastrointestinal Motility Drugs Sales by Country (2021-2026) & (K Units) Table 149. North America Gastrointestinal Motility Drugs Sales by Country (2027-2032) & (K Units) Table 150. North America Gastrointestinal Motility Drugs Revenue by Country (2021-2026) & (US$ Million) Table 151. North America Gastrointestinal Motility Drugs Revenue by Country (2027-2032) & (US$ Million) Table 152. Europe Gastrointestinal Motility Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 153. Europe Gastrointestinal Motility Drugs Sales by Country (2021-2026) & (K Units) Table 154. Europe Gastrointestinal Motility Drugs Sales by Country (2027-2032) & (K Units) Table 155. Europe Gastrointestinal Motility Drugs Revenue by Country (2021-2026) & (US$ Million) Table 156. Europe Gastrointestinal Motility Drugs Revenue by Country (2027-2032) & (US$ Million) Table 157. Asia Pacific Gastrointestinal Motility Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 158. Asia Pacific Gastrointestinal Motility Drugs Sales by Country (2021-2026) & (K Units) Table 159. Asia Pacific Gastrointestinal Motility Drugs Sales by Country (2027-2032) & (K Units) Table 160. Asia Pacific Gastrointestinal Motility Drugs Revenue by Country (2021-2026) & (US$ Million) Table 161. Asia Pacific Gastrointestinal Motility Drugs Revenue by Country (2027-2032) & (US$ Million) Table 162. South America Gastrointestinal Motility Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 163. South America Gastrointestinal Motility Drugs Sales by Country (2021-2026) & (K Units) Table 164. South America Gastrointestinal Motility Drugs Sales by Country (2027-2032) & (K Units) Table 165. South America Gastrointestinal Motility Drugs Revenue by Country (2021-2026) & (US$ Million) Table 166. South America Gastrointestinal Motility Drugs Revenue by Country (2027-2032) & (US$ Million) Table 167. Middle East and Africa Gastrointestinal Motility Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 168. Middle East and Africa Gastrointestinal Motility Drugs Sales by Country (2021-2026) & (K Units) Table 169. Middle East and Africa Gastrointestinal Motility Drugs Sales by Country (2027-2032) & (K Units) Table 170. Middle East and Africa Gastrointestinal Motility Drugs Revenue by Country (2021-2026) & (US$ Million) Table 171. Middle East and Africa Gastrointestinal Motility Drugs Revenue by Country (2027-2032) & (US$ Million) Table 172. Global Gastrointestinal Motility Drugs Sales by Type (2021-2026) & (K Units) Table 173. Global Gastrointestinal Motility Drugs Sales by Type (2027-2032) & (K Units) Table 174. Global Gastrointestinal Motility Drugs Sales Market Share by Type (2021-2026) Table 175. Global Gastrointestinal Motility Drugs Sales Market Share by Type (2027-2032) Table 176. Global Gastrointestinal Motility Drugs Revenue by Type (2021-2026) & (US$ Million) Table 177. Global Gastrointestinal Motility Drugs Revenue by Type (2027-2032) & (US$ Million) Table 178. Global Gastrointestinal Motility Drugs Revenue Market Share by Type (2021-2026) Table 179. Global Gastrointestinal Motility Drugs Revenue Market Share by Type (2027-2032) Table 180. Global Gastrointestinal Motility Drugs Price by Type (2021-2026) & (US$/Unit) Table 181. Global Gastrointestinal Motility Drugs Price by Type (2027-2032) & (US$/Unit) Table 182. Global Gastrointestinal Motility Drugs Sales by Application (2021-2026) & (K Units) Table 183. Global Gastrointestinal Motility Drugs Sales by Application (2027-2032) & (K Units) Table 184. Global Gastrointestinal Motility Drugs Sales Market Share by Application (2021-2026) Table 185. Global Gastrointestinal Motility Drugs Sales Market Share by Application (2027-2032) Table 186. Global Gastrointestinal Motility Drugs Revenue by Application (2021-2026) & (US$ Million) Table 187. Global Gastrointestinal Motility Drugs Revenue by Application (2027-2032) & (US$ Million) Table 188. Global Gastrointestinal Motility Drugs Revenue Market Share by Application (2021-2026) Table 189. Global Gastrointestinal Motility Drugs Revenue Market Share by Application (2027-2032) Table 190. Global Gastrointestinal Motility Drugs Price by Application (2021-2026) & (US$/Unit) Table 191. Global Gastrointestinal Motility Drugs Price by Application (2027-2032) & (US$/Unit) Table 192. Key Raw Materials Table 193. Raw Materials Key Suppliers Table 194. Gastrointestinal Motility Drugs Distributors List Table 195. Gastrointestinal Motility Drugs Customers List Table 196. Gastrointestinal Motility Drugs Industry Trends Table 197. Gastrointestinal Motility Drugs Industry Drivers Table 198. Gastrointestinal Motility Drugs Industry Restraints Table 199. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Gastrointestinal Motility Drugs Product Image Figure 5. Global Gastrointestinal Motility Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Gastrointestinal Motility Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Gastrointestinal Motility Drugs Sales (2021-2032) & (K Units) Figure 8. Global Gastrointestinal Motility Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Domperidone Product Image Figure 10. Metoclopramide Product Image Figure 11. Mosapride Product Image Figure 12. Minaprocaine Bromide Product Image Figure 13. Itopride Product Image Figure 14. Clinic Product Image Figure 15. Hospital Product Image Figure 16. Other Product Image Figure 17. Global Gastrointestinal Motility Drugs Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Gastrointestinal Motility Drugs, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Gastrointestinal Motility Drugs Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Gastrointestinal Motility Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Gastrointestinal Motility Drugs Sales by Region in 2025 Figure 23. Global Gastrointestinal Motility Drugs Revenue by Region in 2025 Figure 24. North America Gastrointestinal Motility Drugs Market Size by Country in 2025 Figure 25. North America Gastrointestinal Motility Drugs Sales Market Share by Country (2021-2032) Figure 26. North America Gastrointestinal Motility Drugs Revenue Market Share by Country (2021-2032) Figure 27. United States Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Gastrointestinal Motility Drugs Market Size by Country in 2025 Figure 31. Europe Gastrointestinal Motility Drugs Sales Market Share by Country (2021-2032) Figure 32. Europe Gastrointestinal Motility Drugs Revenue Market Share by Country (2021-2032) Figure 33. Germany Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Gastrointestinal Motility Drugs Market Size by Country in 2025 Figure 44. Asia Pacific Gastrointestinal Motility Drugs Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Gastrointestinal Motility Drugs Revenue Market Share by Country (2021-2032) Figure 46. China Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Gastrointestinal Motility Drugs Market Size by Country in 2025 Figure 55. South America Gastrointestinal Motility Drugs Sales Market Share by Country (2021-2032) Figure 56. South America Gastrointestinal Motility Drugs Revenue Market Share by Country (2021-2032) Figure 57. Brazil Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Gastrointestinal Motility Drugs Market Size by Country in 2025 Figure 61. Middle East and Africa Gastrointestinal Motility Drugs Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Gastrointestinal Motility Drugs Revenue Market Share by Country (2021-2032) Figure 63. Egypt Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Gastrointestinal Motility Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Gastrointestinal Motility Drugs Sales Market Share by Type (2021-2032) Figure 69. Global Gastrointestinal Motility Drugs Revenue Market Share by Type (2021-2032) Figure 70. Global Gastrointestinal Motility Drugs Price (US$/Unit) by Type (2021-2032) Figure 71. Global Gastrointestinal Motility Drugs Sales Market Share by Application (2021-2032) Figure 72. Global Gastrointestinal Motility Drugs Revenue Market Share by Application (2021-2032) Figure 73. Global Gastrointestinal Motility Drugs Price (US$/Unit) by Application (2021-2032) Figure 74. Gastrointestinal Motility Drugs Value Chain Figure 75. Gastrointestinal Motility Drugs Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Gastrointestinal Motility Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Domperidone
  • Metoclopramide
  • Mosapride
  • Minaprocaine Bromide
  • Itopride
Applications
  • Clinic
  • Hospital
  • Other
Companies covered
  • Zhuhai Rundu Pharmaceutical Co., Ltd.
  • Yabao Pharmaceutical Group Co., Ltd.
  • Sichuan Zilinggong Pharmaceutical Co., Ltd.
  • Shijiazhuang Siyao Co., Ltd.
  • Shandong Xinhua Pharmaceutical Co., Ltd.
  • Shandong Fangming Pharmaceutical Group Co., Ltd.
  • Lunan Beite Pharmaceutical Co., Ltd.
  • Jiangxi Huiren Pharmaceutical Co., Ltd.
  • Jiangsu Jibei Pharmaceutical Co., Ltd.
  • Jiangsu Hausen Pharmaceutical Group Co., Ltd.
  • China Resources Double Crane Pharmaceutical Co., Ltd.
  • Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd.
  • Hainan Asia Pharmaceutical Co., Ltd.
  • Guangdong Annuo Pharmaceutical Co., Ltd.
  • Disa Pharmaceutical Group Co., Ltd.
  • Chenxin Pharmaceutical Co., Ltd.
  • Taj Pharmaceuticals Limited
  • Sumitomo Pharma Co., Ltd.
  • Pfizer
  • Midas Pharma GmbH
  • Janssen Pharmaceutica
  • Hanmi Pharm. Co., Ltd.
  • ANI Pharmaceuticals, Inc.
  • Abbott

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Gastrointestinal Motility Drugs Market Size (2021-2032)
  4. 2.2.2 Global Gastrointestinal Motility Drugs Sales (2021-2032)
  5. 2.2.3 Global Gastrointestinal Motility Drugs Market Average Price (2021-2032)
  6. 2.3 Gastrointestinal Motility Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Domperidone
  9. 2.3.3 Metoclopramide
  10. 2.3.4 Mosapride
  11. 2.3.5 Minaprocaine Bromide
  12. 2.3.6 Itopride
  13. 2.4 Gastrointestinal Motility Drugs by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Clinic
  16. 2.4.3 Hospital
  17. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Gastrointestinal Motility Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Gastrointestinal Motility Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Gastrointestinal Motility Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Gastrointestinal Motility Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Gastrointestinal Motility Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Gastrointestinal Motility Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Gastrointestinal Motility Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Gastrointestinal Motility Drugs, Established Date
  9. 3.9 Global Gastrointestinal Motility Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Zhuhai Rundu Pharmaceutical Co., Ltd.
  2. 4.1.1 Zhuhai Rundu Pharmaceutical Co., Ltd. Company Information
  3. 4.1.2 Zhuhai Rundu Pharmaceutical Co., Ltd. Business Overview
  4. 4.1.3 Zhuhai Rundu Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Zhuhai Rundu Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  6. 4.1.5 Zhuhai Rundu Pharmaceutical Co., Ltd. Recent Developments
  7. 4.2 Yabao Pharmaceutical Group Co., Ltd.
  8. 4.2.1 Yabao Pharmaceutical Group Co., Ltd. Company Information
  9. 4.2.2 Yabao Pharmaceutical Group Co., Ltd. Business Overview
  10. 4.2.3 Yabao Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Yabao Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  12. 4.2.5 Yabao Pharmaceutical Group Co., Ltd. Recent Developments
  13. 4.3 Sichuan Zilinggong Pharmaceutical Co., Ltd.
  14. 4.3.1 Sichuan Zilinggong Pharmaceutical Co., Ltd. Company Information
  15. 4.3.2 Sichuan Zilinggong Pharmaceutical Co., Ltd. Business Overview
  16. 4.3.3 Sichuan Zilinggong Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sichuan Zilinggong Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  18. 4.3.5 Sichuan Zilinggong Pharmaceutical Co., Ltd. Recent Developments
  19. 4.4 Shijiazhuang Siyao Co., Ltd.
  20. 4.4.1 Shijiazhuang Siyao Co., Ltd. Company Information
  21. 4.4.2 Shijiazhuang Siyao Co., Ltd. Business Overview
  22. 4.4.3 Shijiazhuang Siyao Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Shijiazhuang Siyao Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  24. 4.4.5 Shijiazhuang Siyao Co., Ltd. Recent Developments
  25. 4.5 Shandong Xinhua Pharmaceutical Co., Ltd.
  26. 4.5.1 Shandong Xinhua Pharmaceutical Co., Ltd. Company Information
  27. 4.5.2 Shandong Xinhua Pharmaceutical Co., Ltd. Business Overview
  28. 4.5.3 Shandong Xinhua Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Shandong Xinhua Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  30. 4.5.5 Shandong Xinhua Pharmaceutical Co., Ltd. Recent Developments
  31. 4.6 Shandong Fangming Pharmaceutical Group Co., Ltd.
  32. 4.6.1 Shandong Fangming Pharmaceutical Group Co., Ltd. Company Information
  33. 4.6.2 Shandong Fangming Pharmaceutical Group Co., Ltd. Business Overview
  34. 4.6.3 Shandong Fangming Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Shandong Fangming Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  36. 4.6.5 Shandong Fangming Pharmaceutical Group Co., Ltd. Recent Developments
  37. 4.7 Lunan Beite Pharmaceutical Co., Ltd.
  38. 4.7.1 Lunan Beite Pharmaceutical Co., Ltd. Company Information
  39. 4.7.2 Lunan Beite Pharmaceutical Co., Ltd. Business Overview
  40. 4.7.3 Lunan Beite Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Lunan Beite Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  42. 4.7.5 Lunan Beite Pharmaceutical Co., Ltd. Recent Developments
  43. 4.8 Jiangxi Huiren Pharmaceutical Co., Ltd.
  44. 4.8.1 Jiangxi Huiren Pharmaceutical Co., Ltd. Company Information
  45. 4.8.2 Jiangxi Huiren Pharmaceutical Co., Ltd. Business Overview
  46. 4.8.3 Jiangxi Huiren Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Jiangxi Huiren Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  48. 4.8.5 Jiangxi Huiren Pharmaceutical Co., Ltd. Recent Developments
  49. 4.9 Jiangsu Jibei Pharmaceutical Co., Ltd.
  50. 4.9.1 Jiangsu Jibei Pharmaceutical Co., Ltd. Company Information
  51. 4.9.2 Jiangsu Jibei Pharmaceutical Co., Ltd. Business Overview
  52. 4.9.3 Jiangsu Jibei Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Jiangsu Jibei Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  54. 4.9.5 Jiangsu Jibei Pharmaceutical Co., Ltd. Recent Developments
  55. 4.10 Jiangsu Hausen Pharmaceutical Group Co., Ltd.
  56. 4.10.1 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Company Information
  57. 4.10.2 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Business Overview
  58. 4.10.3 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  60. 4.10.5 Jiangsu Hausen Pharmaceutical Group Co., Ltd. Recent Developments
  61. 4.11 China Resources Double Crane Pharmaceutical Co., Ltd.
  62. 4.11.1 China Resources Double Crane Pharmaceutical Co., Ltd. Company Information
  63. 4.11.2 China Resources Double Crane Pharmaceutical Co., Ltd. Business Overview
  64. 4.11.3 China Resources Double Crane Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 China Resources Double Crane Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  66. 4.11.5 China Resources Double Crane Pharmaceutical Co., Ltd. Recent Developments
  67. 4.12 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd.
  68. 4.12.1 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Company Information
  69. 4.12.2 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Business Overview
  70. 4.12.3 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  72. 4.12.5 Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. Recent Developments
  73. 4.13 Hainan Asia Pharmaceutical Co., Ltd.
  74. 4.13.1 Hainan Asia Pharmaceutical Co., Ltd. Company Information
  75. 4.13.2 Hainan Asia Pharmaceutical Co., Ltd. Business Overview
  76. 4.13.3 Hainan Asia Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Hainan Asia Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  78. 4.13.5 Hainan Asia Pharmaceutical Co., Ltd. Recent Developments
  79. 4.14 Guangdong Annuo Pharmaceutical Co., Ltd.
  80. 4.14.1 Guangdong Annuo Pharmaceutical Co., Ltd. Company Information
  81. 4.14.2 Guangdong Annuo Pharmaceutical Co., Ltd. Business Overview
  82. 4.14.3 Guangdong Annuo Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Guangdong Annuo Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  84. 4.14.5 Guangdong Annuo Pharmaceutical Co., Ltd. Recent Developments
  85. 4.15 Disa Pharmaceutical Group Co., Ltd.
  86. 4.15.1 Disa Pharmaceutical Group Co., Ltd. Company Information
  87. 4.15.2 Disa Pharmaceutical Group Co., Ltd. Business Overview
  88. 4.15.3 Disa Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Disa Pharmaceutical Group Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  90. 4.15.5 Disa Pharmaceutical Group Co., Ltd. Recent Developments
  91. 4.16 Chenxin Pharmaceutical Co., Ltd.
  92. 4.16.1 Chenxin Pharmaceutical Co., Ltd. Company Information
  93. 4.16.2 Chenxin Pharmaceutical Co., Ltd. Business Overview
  94. 4.16.3 Chenxin Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Chenxin Pharmaceutical Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  96. 4.16.5 Chenxin Pharmaceutical Co., Ltd. Recent Developments
  97. 4.17 Taj Pharmaceuticals Limited
  98. 4.17.1 Taj Pharmaceuticals Limited Company Information
  99. 4.17.2 Taj Pharmaceuticals Limited Business Overview
  100. 4.17.3 Taj Pharmaceuticals Limited Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Taj Pharmaceuticals Limited Gastrointestinal Motility Drugs Product Portfolio
  102. 4.17.5 Taj Pharmaceuticals Limited Recent Developments
  103. 4.18 Sumitomo Pharma Co., Ltd.
  104. 4.18.1 Sumitomo Pharma Co., Ltd. Company Information
  105. 4.18.2 Sumitomo Pharma Co., Ltd. Business Overview
  106. 4.18.3 Sumitomo Pharma Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Sumitomo Pharma Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  108. 4.18.5 Sumitomo Pharma Co., Ltd. Recent Developments
  109. 4.19 Pfizer
  110. 4.19.1 Pfizer Company Information
  111. 4.19.2 Pfizer Business Overview
  112. 4.19.3 Pfizer Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Pfizer Gastrointestinal Motility Drugs Product Portfolio
  114. 4.19.5 Pfizer Recent Developments
  115. 4.20 Midas Pharma GmbH
  116. 4.20.1 Midas Pharma GmbH Company Information
  117. 4.20.2 Midas Pharma GmbH Business Overview
  118. 4.20.3 Midas Pharma GmbH Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Midas Pharma GmbH Gastrointestinal Motility Drugs Product Portfolio
  120. 4.20.5 Midas Pharma GmbH Recent Developments
  121. 4.21 Janssen Pharmaceutica
  122. 4.21.1 Janssen Pharmaceutica Company Information
  123. 4.21.2 Janssen Pharmaceutica Business Overview
  124. 4.21.3 Janssen Pharmaceutica Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 4.21.4 Janssen Pharmaceutica Gastrointestinal Motility Drugs Product Portfolio
  126. 4.21.5 Janssen Pharmaceutica Recent Developments
  127. 4.22 Hanmi Pharm. Co., Ltd.
  128. 4.22.1 Hanmi Pharm. Co., Ltd. Company Information
  129. 4.22.2 Hanmi Pharm. Co., Ltd. Business Overview
  130. 4.22.3 Hanmi Pharm. Co., Ltd. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  131. 4.22.4 Hanmi Pharm. Co., Ltd. Gastrointestinal Motility Drugs Product Portfolio
  132. 4.22.5 Hanmi Pharm. Co., Ltd. Recent Developments
  133. 4.23 ANI Pharmaceuticals, Inc.
  134. 4.23.1 ANI Pharmaceuticals, Inc. Company Information
  135. 4.23.2 ANI Pharmaceuticals, Inc. Business Overview
  136. 4.23.3 ANI Pharmaceuticals, Inc. Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  137. 4.23.4 ANI Pharmaceuticals, Inc. Gastrointestinal Motility Drugs Product Portfolio
  138. 4.23.5 ANI Pharmaceuticals, Inc. Recent Developments
  139. 4.24 Abbott
  140. 4.24.1 Abbott Company Information
  141. 4.24.2 Abbott Business Overview
  142. 4.24.3 Abbott Gastrointestinal Motility Drugs Sales, Revenue and Gross Margin (2021-2026)
  143. 4.24.4 Abbott Gastrointestinal Motility Drugs Product Portfolio
  144. 4.24.5 Abbott Recent Developments
5 Global Gastrointestinal Motility Drugs Market Scenario by Region
  1. 5.1 Global Gastrointestinal Motility Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Gastrointestinal Motility Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Gastrointestinal Motility Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Gastrointestinal Motility Drugs Sales by Region: 2027-2032
  5. 5.3 Global Gastrointestinal Motility Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Gastrointestinal Motility Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Gastrointestinal Motility Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Gastrointestinal Motility Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Gastrointestinal Motility Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Gastrointestinal Motility Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Gastrointestinal Motility Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Gastrointestinal Motility Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe Gastrointestinal Motility Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Gastrointestinal Motility Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe Gastrointestinal Motility Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Gastrointestinal Motility Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Gastrointestinal Motility Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Gastrointestinal Motility Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Gastrointestinal Motility Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Gastrointestinal Motility Drugs Market Facts & Figures by Country
  41. 5.7.1 South America Gastrointestinal Motility Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Gastrointestinal Motility Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America Gastrointestinal Motility Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Gastrointestinal Motility Drugs Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Gastrointestinal Motility Drugs Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Gastrointestinal Motility Drugs Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Gastrointestinal Motility Drugs Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Gastrointestinal Motility Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Gastrointestinal Motility Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Gastrointestinal Motility Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Gastrointestinal Motility Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Gastrointestinal Motility Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Gastrointestinal Motility Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Gastrointestinal Motility Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Gastrointestinal Motility Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Gastrointestinal Motility Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Gastrointestinal Motility Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Gastrointestinal Motility Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Gastrointestinal Motility Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Gastrointestinal Motility Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Gastrointestinal Motility Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Gastrointestinal Motility Drugs Value Chain Analysis
  2. 8.1.1 Gastrointestinal Motility Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Gastrointestinal Motility Drugs Production Mode & Process
  5. 8.2 Gastrointestinal Motility Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Gastrointestinal Motility Drugs Distributors
  8. 8.2.3 Gastrointestinal Motility Drugs Customers
9 Global Gastrointestinal Motility Drugs Analyzing Market Dynamics
  1. 9.1 Gastrointestinal Motility Drugs Industry Trends
  2. 9.2 Gastrointestinal Motility Drugs Industry Drivers
  3. 9.3 Gastrointestinal Motility Drugs Industry Opportunities and Challenges
  4. 9.4 Gastrointestinal Motility Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst